CD8A and neoplasm: Taken together these data indicate the oral administration of EcN(lpp-OVA) promotes the modification of the tumor infiltrating T cells population by enhancing the frequency of the OVA-specific CD8+ T cells and reducing the amount of FoxP3+ cells.